Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study.

[1]  N. Poolsup,et al.  Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis , 2018, European Journal of Clinical Pharmacology.

[2]  B. Suwelack,et al.  Tacrolimus - Pharmacokinetic Considerations for Clinicians. , 2018, Current drug metabolism.

[3]  A. Ingsathit,et al.  Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study , 2017, International Journal of Clinical Pharmacy.

[4]  C. Sukasem,et al.  Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation , 2015, European Journal of Clinical Pharmacology.

[5]  M. Christiaans,et al.  Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. , 2014, Transplantation.

[6]  Shigeru Satoh,et al.  Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation , 2012, Transplantation.

[7]  D. Abramowicz,et al.  Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation: A Substudy of a Randomized Phase III Trial. , 2012, Therapeutic drug monitoring.

[8]  M. Christiaans,et al.  Pharmacokinetics in Stable Kidney Transplant Recipients After Conversion From Twice-Daily to Once-daily Tacrolimus Formulations , 2012, Therapeutic drug monitoring.

[9]  David W. Johnson,et al.  Once-Versus Twice-Daily Tacrolimus , 2011, Drugs.

[10]  Chi-hung Cheng,et al.  Lower Variability of Tacrolimus Trough Concentration After Conversion From Prograf to Advagraf in Stable Kidney Transplant Recipients , 2011, Transplantation.

[11]  C. Cauffiez,et al.  Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients , 2011, Clinical pharmacokinetics.

[12]  T. Slowinski,et al.  Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations , 2010, Pharmacogenetics and genomics.

[13]  K. Verbeke,et al.  Reduced C0 Concentrations and Increased Dose Requirements in Renal Allograft Recipients Converted to the Novel Once-Daily Tacrolimus Formulation , 2010, Transplantation.

[14]  W. Weimar,et al.  High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  J. Squifflet,et al.  Pharmacokinetics for Once‐ Versus Twice‐Daily Tacrolimus Formulations in De Novo Kidney Transplantation: A Randomized, Open‐Label Trial , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  S. G. Melendreras,et al.  Three-Month Experience With Tacrolimus Once-Daily Regimen in Stable Renal Allografts , 2009 .